What is Geneoscopy?
Geneoscopy Inc. is a specialized life sciences organization dedicated to transforming gastrointestinal health through innovative diagnostic testing. The company's core technology utilizes stool-derived eukaryotic RNA (seRNA) to identify colorectal cancer and precancerous adenomas with high precision. Recognized by the U.S. FDA with Breakthrough Device Designation, Geneoscopy's diagnostic solution is engineered to improve patient outcomes by facilitating earlier detection than traditional noninvasive screening methods. By bridging the gap between complex molecular research and clinical application, the company is effectively addressing a significant unmet need in oncology and preventative medicine, establishing a robust competitive moat in the diagnostic landscape.
How much funding has Geneoscopy raised?
Geneoscopy has raised a total of $217.1M across 4 funding rounds:
Series A
$6.9M
Debt
$150K
Series B
$105M
Series C
$105M
Series A (2019): $6.9M with participation from NT Investments, Lightchain Capital LLC, and Cultivation Capital
Debt (2020): $150K led by PPP
Series B (2021): $105M supported by Nt Investment Academy and Lightchain
Series C (2025): $105M featuring Tri Locum Partners, Bio-Rad Laboratories, Lightchain Capital, Labcorp, PETRICHOR Group, Granger Management, Mercy Health, and Morningside Ventures
Key Investors in Geneoscopy
Labcorp
Labcorp is a global leader in laboratory services, providing comprehensive diagnostic and biopharma laboratory solutions to support clinical decision-making and patient care.
Bio-Rad Laboratories
Bio-Rad Laboratories provides a wide range of innovative tools and services for clinical diagnostics and life science research, focusing on quality control and workflow efficiency.
Lightchain Capital
Lightchain Capital is a venture capital firm specializing in early-stage life sciences, with a dedicated focus on supporting oncology-related innovations and transformative healthcare advancements.
What's next for Geneoscopy?
With the successful closure of this major strategic investment, Geneoscopy is well-positioned to accelerate its commercialization roadmap and expand its clinical footprint. The influx of capital will likely be directed toward scaling manufacturing capabilities, finalizing regulatory requirements for broader market access, and deepening its research pipeline. As the company transitions into a high-growth phase, the focus will shift toward establishing strategic partnerships with healthcare providers and diagnostic laboratories to integrate its seRNA technology into standard clinical workflows. This trajectory suggests a sustained commitment to reducing morbidity through early intervention, further solidifying Geneoscopy's role as a transformative player in the global diagnostics market.
See full Geneoscopy company page
